Brokerages Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $21.56

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $21.5556.

A number of analysts have recently issued reports on ELAN shares. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $18.00 to $24.00 in a research note on Tuesday, October 7th. Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 15th. UBS Group boosted their target price on Elanco Animal Health from $25.00 to $27.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday, November 19th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 1st.

Elanco Animal Health Trading Down 0.5%

NYSE ELAN opened at $21.89 on Monday. The stock’s 50 day moving average is $21.64 and its 200 day moving average is $17.81. The firm has a market capitalization of $10.88 billion, a PE ratio of 364.89, a P/E/G ratio of 2.97 and a beta of 1.86. The company has a quick ratio of 1.23, a current ratio of 2.40 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $23.70.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Research analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Several institutional investors have recently bought and sold shares of the company. SJS Investment Consulting Inc. raised its stake in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares during the last quarter. Huntington National Bank raised its position in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after acquiring an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its position in Elanco Animal Health by 80.3% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after purchasing an additional 900 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 79.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after acquiring an additional 951 shares during the period. Finally, First Horizon Advisors Inc. raised its position in shares of Elanco Animal Health by 184.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after purchasing an additional 2,414 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.